Recent studies reveal significant differences in brain-derived neurotrophic factor (BDNF) and sex hormone levels between chronic antipsychotic-treated male (CATM) schizophrenia (SCZ) patients and healthy controls. Specifically, patients with...
Intranasal Implants: Revolutionizing Schizophrenia Care With Targeted Delivery
The blood-brain barrier poses challenges for central nervous system (CNS) drug delivery, but intranasal administration offers a promising solution by...
Psychosocial Interventions Essential for Addressing Schizophrenia’s Negative Symptoms
Schizophrenia spectrum disorders (SSD) are severe mental health conditions marked by cognitive impairments, poor functional outcomes, reduced quality of life,...
Crystal Hopkins,
DNP, PMHNP-BC, FNP-BC
Founder and CEO, Better Mental Health and Consulting, LLC
Preventing Relapse and Hospitalization in Schizophrenia
The prevention of relapse and hospitalization in schizophrenia is a significant public health challenge. Antipsychotic medications reduce relapse risk, with...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
A review of 22 randomized controlled trials involving 1500 patients with schizophrenia spectrum disorder explored the use of mindfulness-based interventions...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Emerging Treatments for Schizophrenia: Addressing Gaps in Symptom Management and Adherence Challenges
Schizophrenia is a severe condition treated primarily with dopamine-modulating antipsychotics, which mainly address positive symptoms but often fail to manage...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
Predictors of Medication Response in Treatment-Resistant Schizophrenia
A study aimed to identify predictors of medication response in treatment-resistant schizophrenia (TRS) by analyzing baseline patient and study characteristics...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC; Clinical Professor and Chair, College of Nursing, Washington State University
